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LANGERHANS CELLS FACILITATE MUTAGENESIS AND SQUAMOUS
CELL CARCINOMA. Badri G. Modi, Jason Neustadter, Julia Lewis, Renata Filler,
Bernice Kwong, Swapna Reddy, Robert Tigelaar, Daniel Kaplan, Adrian Hayday,
Michael Girardi. Department of Dermatology, Yale University, School of Medicine, New
Haven, CT.
Polyaromatic hydrocarbons (PAHs) are prevalent, potent carcinogens, and 7,12dimethylbenz[a]anthracene (DMBA) is a model PAH widely used to model epithelial
carcinogenesis. To achieve mutagenic effects, DMBA must be activated to DMBA-trans3,4-diol via cytochrome p450 (CYP) 1B1, and this intermediate is the penultimate
carcinogen responsible for inducing the signature mutation in the Hras oncogene.
Recently, we observed that mice deficient in Langerhans cells (LCs), an epidermal
dendritic cell (DC), are almost completely resistant to cutaneous chemical carcinogenesis,
independent of αβ and γδ T cell influences. Investigations to identify the LC contribution
to carcinogenesis revealed that DMBA-exposed LC-intact skin harbor more Hras
mutations than LC-deficient skin, implying an early effect on tumor initiation. In vitro
XS106 cells, a cell line derived from murine LCs, efficiently metabolized DMBA to
DMBA-trans-3,4-diol as detected by liquid chromatography and tandem mass
spectrometry. Moreover, initiation with DMBA-trans-3,4-diol bypassed tumor resistance
and restored tumorigenesis in LC-deficient mice. Consistent with previous reports,
murine and human LCs expressed a higher CYP1B1:CYP1A1 ratio than keratinocytes,
conferring an advantage in the ability to metabolize to mutagenic intermediates. Thus,
our data suggest a cooperative carcinogenesis scenario in which LC generate DMBAtrans-3,4-diol which moves into keratinocytes for further metabolism and mutagenesis.
Tissue-associated DCs – which are also found in other epithelial surfaces – can enhance
chemical carcinogenesis via PAH metabolism, highlighting the complex relation between
immune cells and carcinogenesis.
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I. Introduction
A. EPITHELIAL TISSUES, CANCER, AND THE IMMUNE SYSTEM
Epithelial tissues are situated at critical junctures with the environment and serve
as protective barriers from exogenous insults. Such epithelial linings have evolved an
organizational structure in which the deepest layer of cells, often regarded as the basal
layer and located adjacent to the basement membrane, are regenerative and supply the
more superficial layers with differentiated cells that function in secretion, barrier
protection, or other tissue specific roles [1]. In this dynamic process, the differentiated
cells will ultimately be shed from the surface and replaced by a newly divided cell from
the basal layer. With repeated environmental insults to epithelial tissues, perhaps this
dynamic organizational structure evolved to enable clearing of damaged cells and
maintenance of structural and functional integrity [2]. However, even this dynamic
process frequently falls short of protecting epithelial surfaces from aberrant growth and
tumorigenesis. In humans, more than ninety percent of neoplasms arise in epithelial
tissues [3], which include the skin, gastrointestinal (GI), respiratory, and genitourinary
(GU) tracts. The cutaneous epithelial surface (i.e. epidermis) is the site of the two most
common human cancers [4] [5] – basal cell carcinoma (BCC) and squamous cell
carcinoma (SCC) – and accordingly offers a unique ability to model the biological events
that contribute to carcinogenesis more generally.
Many environmental factors are implicated in promoting the development of
epithelial-derived tumors. For instance, ultraviolet light exposure is largely considered
the major risk factor for cutaneous BCC and SCC. Similarly, polyaromatic hydrocarbons
(PAHs) are well recognized for their tumorigenic potential to skin, lung, GI, and GU
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tumors. PAHs are ubiquitous chemicals in industrialized societies, present in automobile
emissions, tobacco smoke, smoked foods, and ground water [1]. Accordingly, individuals
exposed to occupational levels of PAHs experience up to 1.4 times the risk of lung cancer
and 2.2 times the risk of bladder cancer compared to the normal population [6]. While
perhaps not as important an environmental factor as UVR for the skin, PAHs have been
shown to predispose mice to developing UVR-induced tumors. At doses at which neither
induce tumors alone, the combination of UVR and PAHs results in a higher rate of
tumorigenesis [7]. In addition, the reverse relationship also has been shown, where UVexposed mice are more sensitive to the PAH effects [8]. Due to its ability to induce
tumors, PAHs serve as a means to model both environmental and non-environmental
contributions to cancer through the chemical carcinogenesis protocol discussed below.
In addition to the organizational structure that helps to limit epithelial
transformation, immune surveillance similarly is an important host protective
phenomenon that helps to inhibit carcinogenesis. In support of this, organ transplant
patient on immunosuppressive therapy are 65 to 250 times as likely to develop cutaneous
squamous cell carcinoma than compared to the general population [9]. Consistent in noncutaneous epithelial sites, the risk of squamous cell carcinoma of the anal canal is 120
times higher in HIV-positive patients compared to HIV-negative patients [10]. Several
models demonstrate that mice lacking effector components of the immune system,
including natural killer (NK) cells and natural killer T (NKT) cells, are more susceptible
to PAH-induced tumors than their wild type counterparts [11]. Thus, clinical and
laboratory observations suggest an anti-tumor role for immune system constituents in
cancer biology.
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Within the study of non-melanoma cutaneous cancer biology, several immune
cells are implicated in affecting the development of tumors. Keratinocytes of the
epidermis in mice are in close proximity to two distinct subsets of intraepithelial
lymphocytes (IEL), namely the dendritic epidermal T cells (DETCs) [12] and the
Langerhans cells (LCs). These two cell types form a network of intraepidermal immature
immune cells and their dendritic processes extend to contact keratinocytes, including the
epithelial stem cells in the basal layer and near hair follicles [1, 13].
Girardi, Hayday, and Tigelaar have provided insight into the precise functions of
the γδ DETC constituency of IELs. Mice lacking TCRδ(-/-) DETCs were highly
susceptible to developing chemically-induced tumors compared to wild type mice,
implying their role in the down-regulation of cutaneous malignancies [12, 14]. While αβ
T cells predominantly circulate in the blood and lymphatics in systemic circulation until
recruited to sites of inflammation, γδ DETC have been shown to down-regulate an overexuberant αβ T cell-mediated inflammatory response [12]. While these studies supported
the role of γδ DETCs in regulating carcinogenesis, a similar mouse model of LCdeficiency was not available to examine the role of the Langerhans cell in cutaneous
carcinogenesis, until recently.

B. LANGERHANS CELLS BIOLOGY – THE PAST AND PRESENT
Our understanding of the Langerhans cell has evolved in many ways since
identification in 1868. Paul Langerhans, a German medical student, mistakenly believed
the dendritic processes to suggest he was observing distal nerve cells of the skin [15]. In
1961, Birbeck characterized the tennis racket-shaped organelles present within LC, but he
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regarded the cells as worn out, pigmentless melanocytes. Since then, key experiments
have shifted our understanding of LC. In 1977, Stingle, Rowden, and Klareskog
demonstrated the expression of Fc and complement receptors, and MHCII molecules on
the LC surface, which cemented their classification as immune cells [16-19]. LC were
found to migrate to the lymph node and have varying states of maturation based on
location and antigen stimulation, suggesting a role in antigen presentation. Thus, the
“Langerhans cell paradigm” developed and became the prototype for all tissue-resident
tantigen presenting dendritic cells: the life cycle consists of residing in the skin (or
whichever specific tissue) until encountering an antigen, after which it migrates to a
regional lymph node, and matures to upregulate surface molecules critical for
presentation to T cells [16, 20].
LC are derived from hematopoietic bone marrow cells [21], and the primary
building block of Birbeck granules has been identified as langerin/CD207, a C-type lectin
whose exact function is still unclear. The identification of CD207 has advanced the field
of LC biology in two important ways [22]. First, it allows for antibody-mediated
fluorescent tagging against CD207 which enabled visualization of the cells. Secondly,
CD207 represented an LC-specific molecule that could serve as a target for the
generation of an LC-deficient mouse model.
One approach to depleting LC is the “huLangerin-DTA” (DTA) strategy and was
developed by Dan Kaplan at Yale University. In this strategy, the active subunit of the
diphtheria toxin is expressed under the control of the huLangerin promoter, which results
in the selective ablation of epidermal langerin+, MHCII+ cells [23]. Along with other
approaches to ablating LC, these LC-deficient models revealed the existence of two
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distinct populations of langerin+ skin cells – one localized to the epidermis and one
localized to the dermis [24, 25]. With the advent of LC-deficient models, the
understanding of LC-biology has further evolved and become more complex. Although
the classic LC-paradigm would predict an LC-deficient mouse to develop a mitigated
contact hypersensitivity (CHS) response, the LC-deficient DTA mouse model in fact
developed a heightened CHS response as compared to wild type controls [23]. This and
other data supported a role of LC in down-modulating the CHS response, while dermal
langerin+ DC were important for stimulating the response [16, 22, 26].

C. LC-DEFICIENCY AND CHEMICAL CARCINOGENESIS
Similar to the predictions of the DTA mouse in the CHS experimental model, the
classic LC-paradigm would expect the absence of an LC-mediated anti-tumor immune
response. Just as tumor burden is higher in the absence of effector γδ DETCs, one might
expect greater tumorigenesis in the absence of LC-mediated immune induction. The
Girardi lab performed the first investigations of chemical carcinogenesis in LC-deficient
mice. Strikingly, they observed the near elimination of tumors in the DTA cohort
compared to wild type. Under low dose chemical protocols, wild type mice harbored
many tumors by week 14 while more than 50% of DTA mice remained tumor free even
at 16 weeks. The tumor-protective effect in the absence of LCs persisted even at high
dose chemical protocols [27].
Invoking the latest developments in our understanding of the role of dermal and
epidermal langerin+ DC in adaptive immunity induction, one might predict that the
absence of LC would substantially decrease LC-mediated immune tolerance and increase
dermal DC-mediated anti-tumor immunity induction. It would follow, then, that DTA
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mice may be more effective at eliminating early transformed cells through heightened
immune surveillance. However, the Girardi lab also demonstrated that even in the
absence of αβ T cells – the effector arm of an adaptive immune response against
transformed cells – LC-deficiency nearly eliminated tumorigenesis [27]. Thus, the tumor
protective effect afforded by LC-deficiency in the DTA mouse occurred independent of
an anti-tumor immune response.
These findings raised a fundamental question about the role of LC in
carcinogenesis, particularly when induced by PAH. If not an effect on the induction of
anti-tumor immunity, then what other roles could LC play that might affect
carcinogenesis? These studies suggested an under-emphasized role of LC early in
carcinogenesis, likely during tumor initiation. In order to further understand the LC-effect
on tumorigenesis, we must first take a closer look at the experimental model in which this
finding occurs.

D. TWO-STAGE CHEMICAL CARCINOGENESIS
By employing the tumorigenic influences of PAHs, the chemical carcinogenesis
experimental model has yielded many insights into the fundamental influences on cancer
development [28]. Wild type mice on the FVB background are highly susceptible to
chemical carcinogenesis in a reproducible fashion [29]. As such, these rates can be
compared to the level of tumor development in a genetically altered mouse with a
specific phenotype undergoing identical chemical treatment. Varying rates of
tumorigenesis implicates the phenotype of influencing cancer development.
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One major limitation to the complete carcinogenesis model is the inability to
deduce the mechanism of the effect. A variation called two-step chemical carcinogenesis
circumvents this issue by temporally separating the multi-stage process of carcinogenesis
into tumor initiation and tumor promotion. Rather than application of a single
carcinogenic dose to induce tumors, sub-carcinogenic doses of PAHs can be used for
tumor initiation followed by subsequent treatment with a pro-inflammatory agent for
tumor promotion. Thus, experiments may be designed to measure effects on initiation
only, promotion only, or both [30-32].
7,12-dimethylbenz[a]anthracene (DMBA) is a very commonly used and well
described tumor initiating agent. As a result of treatment with DMBA, critical genes in
epidermal keratinocyte oncogenes acquire mutations, and such cells are considered
“transformed”. They will not go on to form tumors without a stimulus for clonal
expansion, which will be provided by the tumor promoting agent. Tumor initiation has
several prerequisites: DMBA must diffuse through the stratum corneum, enter into
keratinocyte stem cells that are thought to be the primary tumor cell, be bioactivated to
the downstream intermediate called DMBA-3,4-dihydrodiol-1,2-epoxide (DMBADE)
which is ultimately mutagenic [33], and interact with critical regions of DNA. The Hras
oncogene appears to be DMBA’s primary target gene and results in an activating
mutation that can be detected as early as 3-4 weeks after DMBA [34] exposure as well as
in the majority of papillomas. After bioactivtation, DMBA intermediates induce a
signature A  T transversion mutation in codon 61 [35, 36]. Assays have been
developed to quantify initiation by measuring the level of DNA-DMBA adducts, DNA
damage, Hras1 mutations, and many others.
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The molecular effects of tumor promoting agents such as TPA are more
pleiotropic. In general, treatment leads to sustained epidermal hyperplasia as evidenced
by increased number of nucleated cell layers and increased thickness, accompanied by an
enhanced cell turnover rate [37]. Importantly, initiated cells – that is, those that have
acquired the critical mutations – are thought to have a survival and proliferative
advantage that results in the selective expansion of the transformed clone while noninitiated cells undergo a normal keratinocyte life cycle of division, differentiation, and
death [28].

E. DMBA METABOLISM
As mentioned previously, DMBA is a parent compound that must be metabolized
to the ultimate carcinogen DMBADE in order to induce the critical Hras mutations.
While DMBA at high concentrations can be toxic to cells, it is not mutagenic without
metabolic activation by inducible enzymes including cytochrome p450 (Cyp) family
members and microsomal epoxide hydroxylase (mEH). Upon entering a cell, DMBA and
other PAHs are high-affinity ligands for the cytosolic aryl hydrocarbon receptor (AhR), a
ligand-activated transcription factor that can enter the nucleus and activate the expression
of xenobiotic response elements (XRE). These include enzymes important for DMBA
metabolism such as Cyp1a1, Cyp1b1, mEH, and aryl hydrocarbon receptor repressor
(AhRR).
Diagram 1 shows the pathway of DMBA metabolism to DMBADE and the
important enzymes. The XRE enzymes are responsible for either unleashing the toxicity
of DMBA by converting to pro-mutagen, or conversely protecting the cell by
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metabolizing to other inert intermediates [38]. Accordingly, the collective efforts of
several investigations demonstrate that mutagenicity and toxicity require a three-step
reaction to generate DMBADE [38-41].
CYP1A1 and CYP1B1 are expressed in varying amounts in different tissues, and
are very efficient at metabolizing PAH [42]. The development of gene knockout mice in
which single XRE enzymes are eliminated has facilitated a clearer understanding of the
DMBA metabolism pathway [43]. Heidel et al investigated the susceptibility of Cyp1B1null mice to mutagenesis, in which Cyp1A1 expression remained intact. After systemic
DMBA treatment, they observed that bone marrow cells did not generate the DNAadducts seen in wild type mice. CYP1A1, in fact, metabolizes DMBA at a higher rate
than CYP1B1. However, given the lack of tumors with sustained Cyp1A1 activity, it
appears that CYP1A1-mediated DMBA metabolism plays no role in mutagenesis as
quantified by DNA adducts [38, 44].
Furthermore, Buters et al demonstrated that Cyp1B1-null mice were almost
completely protected from the acute bone marrow cytotoxic and leukemic effects of
DMBA, despite the continued metabolism by hepatic CYP1A1. Thus, collectively, it
follows that early conversion by CYP1B1 was a requirement for DMBA-induced bone
marrow toxicity and mutagenisis [44-46]. Kleiner et al recapitulated these findings in
mouse epidermis. Direct application of DMBA to a Cyp1B1-null mouse resulted in 64%
reduction in DNA-adduct formation, with similar results seen in the AhR-knockout
mouse [47]. Cyp1B1-null mice also developed no chemically-induced squamous cell
carcinoma in contrast to wild type mice [38].
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After the initial CYP1B1-mediated conversion to DMBA-3,4-epoxide, mEH
immediately converts it to the penultimate carcinogen DMBA-trans-3,4-diol [48]. Miyata
et al demonstrated that embryonic fibroblast from mEH-null mice are unable to generate
DMBA-trans-3,4-diol and are more resistant to DMBA toxicity than fibroblasts from
wild type mice. By showing that mEH-null mice are almost completely resistant to
developing DMBA-induced tumors, they demonstrated that mEH is required for DMBA
carcinogenesis for its role in generation of the proximate carcinogen [49]. The final
conversion from DMBA-trans-3,4-diol to DMBADE is catalyzed by either CYP1B1 or
CYP1A1. The bay region of DMBADE is the ultimate carcinogen that interacts with
DNA [33, 38].

Diagram 1: DMBA metabolism pathway.

Image removed in consideration of US Copyright Law
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F. SITE OF DMBA METABOLISM IN THE EPIDERMIS
Stem cell keratinocytes of the basal layer adjacent to hair follicles are implicated
as the cell of origin for skin cancer [50]. These cells express CYP1B1, CYP1A1, mEH,
and other XRE enzymes, all of which are important to unleash the mutagenicity of
DMBA. Because downstream metabolites were shown to be extremely reactive, it was
the widely held view that DMBA’s intermediates could not exist long enough to diffuse
out of cells [51]. Thus, XRE within keratinocytes were implicated in activating DMBA.
Kuroki and colleagues supported this hypothesis by demonstrating that primary human
keratinocytes incubated with the PAH benzo[a]pyrene (BP) could generate HPLCidentified metabolites of BP. The addition of V79 Chinese hamster cells to this culture
formed their mutagenesis assay, which correlated ouabain resistance in previously
sensitive hamster cells as a proxy for tumor initiation. Hamster cells incubated with BP
and keratinocytes resulted in greater ouabain resistance than hamster cells with just BP
[52, 53].
However, there are significant concerns in accepting the hypothesis that
keratinocytes are the major contributor to DMBA activation. First, the assumption that
activated intermediates are too unstable to exist for a prolonged period of time has not
been supported. DMBA-trans-3,4-diol is available in a stable form for experimental use.
In addition, the concept of intercellular metabolite transfer has been proposed in a
number of experiments investigating the effects of DMBA on bone marrow cells.
Supernatant from AhR+ bone marrow stromal cells cultured with DMBA can induce
apoptosis in bone marrow B cells, while directly incubating B cells with DMBA cannot
[54]. This finding suggests the stability of the intermediate over time and during
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intercellular transfer. Furthermore, the direct application of DMBADE in the absence of
stromal cells was sufficient to induce an apoptosis profile in B cells, providing evidence
that the stromal cells metabolize DMBA and transfer a stable intermediate to the B cells
[55].
The XRE expression profile of the DMBA-relevant enzymes has been reported in
a cell type specific fashion of human epidermal cells. After isolating keratinocytes and
LC from the epidermis of six human donors, the expression of CYP1A1 and CYP1B1
mRNA relative to GADPH control (expressed as +, ++, or +++) was determined for each
cell type. Each enzyme was detected in both cell types, however keratinocytes expressed
greater levels of Cyp1A1 (+++) than Cyp1B1 (++) while the LC expressed greater levels
of Cyp1B1 (+++) than Cyp1A1 (+, almost undetected) [56]. Taken together, these data
suggest that CYP1B1 is required for generation of the penultimate mutagen. It also
follows that LC might be better-equipped enzymatically to facilitate DMBA-mutagenesis
than keratinocytes.
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II. Statement of Purpose and Hypothesis
Our understanding of LC biology has undergone significant changes since
identification of the cell in the mid-1850s. The discovery that LC-deficient DTA mice are
resistant to two-stage chemical carcinogenesis offers the possibility for yet another
advancement to our understanding of LCs and cutaneous biology. Exclusive of immune
surveillance, a mechanism by which LCs influence chemical carcinogenesis has never
been described and is precisely the major aim of this investigation. We hypothesize that
the LC effect will localize early in tumor initiation and that, because of the high
ratio of Cyp1B1:Cyp1A1 expression, LCs are better equipped to perform the
requisite DMBA bioactivation necessary for cutaneous chemical carcinogenesis. The
investigations detailed herein should demonstrate the following:
1) LC-deficiency abrogates chemical carcinogenesis in the absence of both αβ and
γδ T cells, thereby excluding enhanced T cell mediated tumor immune
surveillance to explain tumor resistance.
2) With the use of a K5Hras transgenic mouse, we observed that the protective effect
seen in LC-deficiency likely localizes to tumor initiation rather than tumor
promotion.
3) To show directly that LC-deficiency influences tumor initiation, we employed a
novel real time PCR assay to demonstrate that DMBA-exposed LC-deficient mice
harbor fewer Hras mutations than DMBA-treated wild type mice.
4) When cultured with DMBA in vitro, the Langerin+ / MHCII+ / Birbeck granule+
LC line, XS106, can generate DMBA-trans-3,4-diol.
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5) With data suggesting that LCs contribute to tumor initiation by converting DMBA
to its mutagenic metabolites, we initiated DTA mice with DMBA-trans-3,4-diol
followed by several weeks of TPA promotion and observed a restoration of
tumorigenesis.
6) We examined the XRE mRNA expression profiles present in murine and human
keratinocytes and LCs after exposure to DMBA in culture, and with the support of
existing data in the literature, suggest a mechanistic rationale for why LC
metabolism is required for and keratinocytes metabolism is insufficient for
carcinogenesis.
7) LC-deficiency does not confer resistance to UVB-carcinogenesis, however these
mice develop tumors later than LC-intact mice.
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III. Methods
A. ANIMALS AND HOUSING
All of the in vivo studies were approved by the Yale Animal Care and Use
Committee. FVB/N mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). FVB/N Langerhans cell deficient (Lang-DTA) mice were generated with a bacterial
artificial chromosome-based transgene containing human Langerin which was modified
to drive expression of diphtheria toxin subunit A from an internal ribosome entry site that
was inserted in the 3’ untranslated region of the langerin gene (2). TCRδ-/-, TCRβ-/TCRδ-/-, and K5Hras transgenic (K5HrasTg) were backcrossed onto the FVB/N
background for >10 generations and were previously described (15). TCRδ-/- Lang-DTA,
TCRβ-/-TCRδ-/- Lang- DTA, and K5HrasTg Lang-DTA mice were generated by
intercrossing the respective mutants. Mice were maintained under specific pathogen-free
conditions and food and water provided ad libitum. The animal facility is accredited by
the Association for Assessment of Laboratory Animal Care.
Renata Filler, Jason Neustadter, and Julie Lewis managed mouse colonies and directed generation of
the various strains. Badri Modi, Swapna Reddy, and Bernice Kwong, assisted in house keeping issues
and participated in care of animals.

B. MICE SORTING AND GENOTYPING
Approximately 7-12 days after birth, mice were numbered via toe clipping and
tails were harvested for DNA extraction and subsequent PCR-based genotyping. DNA
was isolated from tail specimens using the QIAGEN DNeasy® Blood and Tissue kit and
according to protocol for purification of DNA from animal tissues on page 28 of DNeasy
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Blood & Tissue Handbook (07/2006). DNA was amplified with a commercially available
PCR master mix and 5’, 3’ primers specific for the DTA transgene and TSH transgene.
After 30 cycles of PCR, DNA was mixed with ethydium bromide dye and run on a 3%
agarose electrophoresis gel along with a 1kb ladder and a positive control sample (DNA
from known huLang-DTA). Thus, DNA samples, and their corresponding mice, were
identified as transgenic+ (tg) or normal littermate control (NLC). Mice were subsequently
sorted to house roughly equal numbers of Tg and NLC per cage.
Badri Modi, Renata Filler, Jason Neustadter, Swapna Reddy, and Julia Lewis all participated in
sorting and genotyping of mice for the various experiments. Badri Modi was involved in data
analaysis and figure representation for all experiments.

C. CHEMICAL CARCINOGENESIS:
All mice undergoing two-stage chemical carcinogenesis were treated as
following, according to previously published protocols [57]. At seven weeks of age, the
hair of a 4x3cm rectangular area on the dorsal surface was clipped with an electric
shaver, being careful not to cause trauma to the skin. The area was treated with Nair® for
approximately one minute, which was washed off with water and paper towel. Dorsal
skin was dried and mice were placed back into cage. One week later, at eight weeks of
age, each mouse was treated with initiating agent – either DMBA or DMBA-trans-3,4diol – reconstituted in acetone. For each experiment, equimolar amounts of initiating
agent were applied to clipped and naired dorsal skins of NLC and DTA cohorts. At 9
weeks of age, the mice received twice weekly treatment with equimolar amounts of TPA
reconstituted in ethanol for the duration of the experiment. The dorsal skin was observed
for tumor development once a week, and tumors counted, measured for area, and
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clinically scored as papillomas (well demarcated, symmetrical, pedunculated, or domeshaped papules without erosion or ulceration) or carcinoma (poorly demarcated,
assymetrical, sessile or dome-shaped with erosions or ulcerations). At the end of the
experiment, representative tumors were harvested from each mouse for subsequent
histologic analysis.
Badri Modi did the two-stage carcinogenesis experiments with D-3,4-tD as initiating agent, including
the mouse sorting, genotyping, chemical treatments, tumor charting, and tumor harvesting. Other
two-stage carcinogenesis experiments were carried out by Jason Neustadter, Renata Filler, and Julia
Lewis. Badri Modi was involved in data analaysis and figure representation for all experiments.

D. CELL CULTURE
RPMI 1640, DMEM, and media supplements were from Invitrogen, Carlsbad, CA
unless otherwise noted. CRPMI media was made by supplementing RPMI 1640 with
10% heat- inactivated FBS, 10mM Hepes, 1% non-essential amino-acids, 2 mM Lglutamine, 1 mM sodium pyruvate, 0.05 mM -mercaptoethanol, and antibiotics). Mouse
keratinocyte (mKC) cells were provided by Yale Dermatology Cell Culture Facility.
CarC cell line (kindly provided by Dr. A. Balmain, UCSF, CA), homozygous for Hras
codon 61 CAA->CTA mutation, was maintained in DMEM media supplemented with
10% FBS, 10mM Hepes, 2mM L-glutamine and antibiotics. XS106 and NS46/NS47 cell
lines were kindly provided by Dr. A. Takashima, U of Toledo, OH. NS46/NS47 cells
were grown in CRPMI, and the media supernatant was used to supplement media for
XS106 cells. XS106 cells were grown in “XS106 media” (CRPMI supplemented with 5%
NS46/NS47 supernatant and 0.5 ng/ml mouse GM-CSF (PeproTech, Rocky Hill, NJ.)
Julia Lewis and Renata Filler did the experiments assessing in vitro XS106’s ability to metabolize
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DMBA. Badri Modi was involved in data analysis and figure representation.

E. ISOLATION OF GENOMIC DNA
Genomic DNA (gDNA) was isolated from cells using DNeasy Blood & Tissue kit
(Qiagen, Valencia, CA) as per manufacture’s protocol. Mice were sacrificed at a specific
time point after dorsal skins received chemical treatment. Using blade and scissors, full
thickness and area of chemically treated murine dorsal skin was excised and the
subcutaneous fat was scraped off. The gDNA of the remaining dermis and epidermis was
isolated using the Gentra® Puregene Tissue Kit (Qiagen) as per manufacture’s protocol.
Each sample underwent further purification via phenol-chloroform-isoamyl extractions
followed by precipitation with ethanol and 3M sodium acetate. Isolated cell and tissue
gDNA was analyzed with a NanoDrop (Thermo Scientific, Wilmington, DE) for purity
and concentration.
Renata Filler, Jason Neustadter, and Badri Modi isolated genomic DNA for experiments presented in
this manuscript.

F. HRAS CLONING AND MUTANT SPECIFIC REAL-TIME PCR
To quantify the number of DMBA-induced codon-61 Hras CAA->CTA
mutations, mutant-specific primers 5’-CTAAGCCTGTTGTTTTGCAGGAC and 3’CATGGCACTATACTCTTCTA [34] and a custom TaqMan probe 5’6FAMCGGAAACAGGTGGTCAT-MGB3’ were designed as part of a novel real-time PCR
assay. TaqMan real-time PCR was run on ABI 7500 using SDS 1.4 and SDS 2.0 software
and TaqMan Gene Expression Master mix (all from ABI Life Technologies Corporation,
Carlsbad, CA) as per manufacture’s protocol with validation slope of ΔCt vs. log input of
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0.078 (ABI Guide to Performing Relative Quantitation of Gene Expression Using RealTime Quantitative PCR). Obtained Ct values were normalized against β-actin and
expression difference was calculated using the equation RQ=2−ΔΔCt. Serial dilution of
gDNA from the CarC into aliquots of mKC gDNA provided additional validation of
TaqMan assay sensitivity. For further verification and validation of the assay, Hras
240bp PCR product containing codon 61 was cloned from CarC and mKC gDNA and
singly inserted into pcDNA6.2TM/GW/D-TOPO® expression vector (Invitrogen,
Carlsbad, CA) and sequenced (W.M. Keck BRL, Yale University). Serial dilutions of a
known number of plasmids and TaqMan real-time PCR were conducted to generate
standard curve. Once assay was validated for specificity in Hras-mutant detection, DNA
from DMBA-treated skins were used in the assay to determine number of Hras mutations
present in an equimolar amount of DNA.
Renata Filler, Julia Lewis, Jason Neustadter and Bernice Kwong were involved in the
development and verification of the assay. Badri Modi used this assay to run other key experiments
for development of concepts and was involved with data analysis / representation in figure.

G. GENE EXPRESSION ANALYSIS
For murine cell line and freshly isolated Langerhans cells:
Real- time quantitative RT-PCR (ABI 7500) using SDS 2.0 software was
performed on RNA isolated using RNeasy Micro kit (Qiagen) from XS106 cells and
purified Langerhans cells. DNA-free RNA was transcribed using High-Capacity cDNA
Reverse Transcription kit as per manufacturer’s protocol and used in downstream
TaqMan assays with TaqMan Gene Expression Master Mix (all from ABI). Obtained Ct
values were normalized against β-actin and expression difference to untreated samples
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was calculated using RQ = 2-ΔΔCt equation.
For human keratinocytes and Langerhans cells:
RNA was isolated with RNeasy (Qiagen) kit and was treated with Ambion Turbo
DNase and then RT Mastermix (ABI) to generate cDNA.Quantitative RTPCR was
performed on an ABI Prism 7900HT cycler with SYBR Green. Quantitect Primer assays
from Quiagen were used for quantification of Cyp1a1, Cyp1b1 and β-actin.
Experiments were carried out by Renata Filler and Julia Lewis. Badri Modi and Julia Lewis
developed the hypothesis that Cyp1B1 to Cyp1A1 ratio explains why LC-specific metabolism is
required for DMBA mutagenesis and carcinogenesis.

H. HPLC AND LC/MS/MS.
For HPLC XS106 cells were incubated with varying DMBA concentrations of 0,
4, 16 or 64 µM at 37°C for 24 hr. An additional cell sample containing 16 µM DMBA
with no cells was incubated under identical conditions. Another sample with XS106 cells
and 16 µM DMBA was incubated for only 1 hour. HPLC studies were performed by Yale
W.M. Keck BRL. In brief, to calibrate HPLC equipment and determine standard
detection times and peak detection heights for DMBA and (+/-)-anti DMBA-3,4dihydrodiol-1,2-epoxide (DMBADE), obtained from the NCI Chemical Carcinogen
Reference Standard Repository, standard concentrations of DMBA and DMBADE at 4,
8, 16, 32 and 64 µM were prepared in 30% methanol. 50 µl of each was injected onto the
HPLC system in an identical manner as for the experimental samples. For LC/MS/MS
detection and quantification XS106 cells were incubated for 24 hr in F10 media (which
has reduced tryptophan concentration) with 10% dialyzed FBS (both from Sigma), 10mM
Hepes, 1% non-essential amino-acids, 2mM l- glutamine, 1mM sodium pyruvate, 0.05
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mM β-mercaptoethanol, antibiotics, 5% NS46/NS47 supernatant, and 0.5 ng/ml mouse
GM-CSF. The following day 32 µM or 64 µM of DMBA was added to the cultures and
allowed to incubate for additional 24 hr after which media and cells were harvested and
sent to Lining Cai and Peter Fu (Biotranex, FDA). Following extraction, samples were
analyzed using LC/MS/MS methods developed by Biotranex to quantify the amount of
DMBA-trans-3,4-diol.
Experiments were carried out by Renata Filler, Julia Lewis, and Jason Neustadter. Badri Modi was
involved with data analysis and figure representation.

I. CHRONIC UV EXPERIMENT
Ten huLang.DTA.FVB and ten NLC.FVB mice at 8 weeks of age were shaved
and sorted for this experiment. Three days later, mice were exposed to UVB from three
broadband FS20T12-UVB lamps filtered through a Kodacel filter (Eastman Kodak) to
remove wavelengths below 290nm [58]. Mice were exposed to 500 J/m2 for three days
during the first week. During the second week, mice were exposed to 750 J/m2 for two
days and then 1000 J/m2 for three days. Then, mice were exposed to 1250 J/m2 for five
days per week, for the next 29 weeks.
Badri Modi carried out all aspects of this experiment, with planning and guidance from others.

Michael Girardi designed and directed most of the planning, troubleshooting, and analysis
of all experiments.
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J. STATISTICS
Statistical significance was evaluated by the two-tailed, unpaired Student’s t-test.
Graphical data is shown with bars indicating standard errors of the mean.
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IV. Results
A. Resistance to two-stage chemical carcinogenesis is αβ and γδ T cell independent
The dramatic tumor resistance observed in TCRβ(-/-).huLang-DTA mice
provided early evidence that the impact of LC-deficiency are independent of adaptive
immunity. However, because LC can express T cell suppressive cytokines such as IL-10
[59, 60], we still considered the possibility that the absence of LC led to an augmented Tcell mediated anti-tumor immune response and, accordingly, abrogation of tumors. γδ T
cells are intraepithelial lymphocytes, unique from the systemically circulating αβ T cells,
that have been shown to regulate chemical carcinogenesis [14]. TCRδ−/− developed
more tumors after DMBA/TPA than their counterparts. To further examine the role of the
adaptive immune response’s effector T cells in LC-deficiency, chemical carcinogenesis
was induced in (Figure 1A) Tcrβ−/− Tcrδ−/− Lang-DTA mice using 50 mg DMBA to
initiate and 6.25 mg TPA/week to promote, as well as in (Figure 1B) Tcrδ−/− Lang-DTA
mice using100 mg DMBA to initiate and 25 mg TPA/week to promote. Even in the
absence αβ and γδ T cells, LC-deficiency conferred a dramatic resistance to two-stage
chemical carcinogenesis.
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Figure 1:

B. LC-deficiency does not prevent tumorigenesis in K5Hras mice
The K5Hras transgenic mouse expresses a constitutively activated Hras gene
within basal keratinocytes. When expressed on the FVB background, many of these mice
will be tumor-positive within three weeks after birth and develop early-onset squamous
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cell carcinoma [61], in the absence of any chemical exposure. Since these mice are
effectively already initiated, we investigated if the absence of LC would eliminate
tumors. Therefore, we crossed huLang-DTA.FVB x K5Hras.FVB and compared rates of
tumorigenesis in the double transgenic mice with the K5Hras.FVB mice. Both cohorts
developed tumors at a similar rate with a non-significant difference in percentage of
tumor-free mice and average tumor area per animal (Figure 2). The huLang-DTA
transgene had no significant effect on rate of tumorigenesis in the K5Hras.FVB mouse.
Thus, the tumor-protective effect seen in LC-deficiency could not overcome the
tumorigenic fate of an “initiated” background, suggesting that LC influence acquisition of
Hras mutations rather than tumor promotion.

Figure 2:
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C. DMBA induces fewer Hras mutations in LC-deficient mice than in wild type mice
At this point, we strongly believed that the LC-effect occurred early in
carcinogenesis, yet we lacked direct evidence demonstrating this. Thus, our lab devised a
novel TaqMan real time polymerase chain reaction (RT-PCR) based mutagenesis assay –
modified from a previous report [34] – that would enable the relative quantification of
Hras mutations in DMBA-treated DTA and WT mice. The assay utilized TaqMan probes
and primers that would selectively amplify and quantify only the alleles harboring the
signature DMBA induced codon 61 Hras mutation.
We first verified the validity of the mutagenesis assay using plasmids and DNA
from the CarC cell line, which harbors two mutant Hras alleles. Hras 240bp PCR product
containing codon-61 was cloned from CarC (mutant Hras) and mKC (WT Hras) cell
gDNA and inserted into pcDNA6.2TM/GW/D-TOPO® expression vector and sequenced
for verification (Figure 3A). Knowledge of the plasmid sequence enabled derivation of
plasmid mass (1plasmid = 5.486E-18 grams, or 18227 plasmids in 0.1pg). Thus, by
running RT-PCR on serial dilutions of known number of mutant plasmids mixed, we
were able to determine the lower limit of mutant allele detection. The assay could detect
as few as 8 mutant plasmids (Figure 3B). The sensitivity of the assay was not affected by
the presence of wild type Hras sequences. Thus, the novel mutagenesis assay was
effective at detecting and quantifying the relative number of Hras mutants present in a
given sample.
With the assay validated, the focus shifted back to examining DTA and WT mice
for relative amounts of mutant Hras present in their DMBA-treated epidermis. This
would directly investigate if LCs have an effect on Hras mutation acquisition. Both

27
cohorts of mice were treated with DMBA, followed by 2 weeks, 4 weeks, or 6 weeks of
TPA. Previous attempts at identifying Hras mutant alleles in non-promoted skin were
unsuccessful (data not shown); therefore, minimal and equal amounts of TPA were used.
DNA was harvested from the DMBA-treated regions of each group and purified for
analysis in the mutagenesis assay. For each TPA cohort, significantly fewer Hras
mutations were detected in DTA mice compared to WT mice, and this result was
unaffected by the absence of T cells (Figure 3C). Thus, in a T-cell independent fashion,
LC-deficiency protected against the acquisition of DMBA-induced epidermal Hras
mutations.

Figure 3:

C
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D. XS106 cells cultured with DMBA generate DMBA-trans-3,4-diol
Considering the events that must take place prior to acquisition of Hras mutations
during chemical carcinogenesis, the major events include DMBA diffusion through the
stratum corneum, metabolic activation to mutagenic intermediates, and interaction with
DNA. Previous reports examining the DTA mouse epidermis revealed no structural
differences compared to a wild type mouse except the absence of LC [23]. Pre-treatment
epidermal and stratum corneum combined thickness is largely equivalent between DTA
and NLC mice [27]. Thus, we focused our efforts at assessing the possible role LC may
play in the bioactivation of DMBA.
In order to investigate the capacity for LC to generate mutagenic intermediates,
XS106 cells, which are stable cell lines derived from murine LC [62], were cultured with
DMBA for 24 hours. High-performance liquid chromatography (HPLC) analysis of cell
lysates revealed internalization of DMBA, while analysis of supernatant identified
DMBA metabolites (Figure 4, A and B). The concentration of XS106-internalized
DMBA increased with increasing initial DMBA concentrations (Figure 4C). Notably,
there was a very rapid accumulation of DMBA metabolites in the medium of XS106
cells, which also increased over time and with the concentration of DMBA (Figure 4, D
and E). These data are consistent with the cells’ uptake and metabolism of DMBA and
the rapid release of metabolites. Liquid chromatography / tandem mass spectrometry
(LC/MS/MS) identified the mutagenic metabolite DMBA-trans-3,4-diol in the cultures,
at mean concentrations of 29.2nM and 42.4nM when initial DMBA concentrations were
32µM and 64µM, respectively (Figure 4F). Thus, the LC-derived XS106 cells are able to
generate the specific intermediates required for mutagenesis.
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Figure 4:

E. Initiation with DMBA-trans-3,4-diol restores tumorigenesis in the DTA mouse
After observing that in vitro LC can generate mutagenic intermediates, we aimed
to investigate directly whether the LC-requirement for tumorigenesis reflected the cells’
release of DMBA metabolites. We initiated WT and DTA mice with 100µg DMBAtrans-3,4-diol followed by standard promotion with TPA. Unlike the resistance observed
after DMBA initiation, DTA mice were susceptible to tumorigenesis at a comparable
level to WT when initiated with the DMBA-trans-3,4-diol (Figure 5). The restoration of
tumors with metabolite initiation demonstrated that the LC-requirement for chemical
carcinogenesis can be bypassed by artificially providing metabolism. Not only do these
findings demonstrate the importance of LC-specific metabolism for carcinogenesis, but
they also highlight the inadequacy of KC metabolism for DMBA tumorigenesis.
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Figure 5:
A

B

C

F. Keratinocyte XRE expression favors Cyp1A1, while LCs expression favors
Cyp1B1
In considering the ability of keratinocytes and LCs to metabolize DMBA, we
investigated the XRE expression profile of primary murine keratinocyte and primary
murine LCs before and 24-hours after DMBA exposure. After creating epidermal cell
suspensions of DMBA-unexposed and -exposed skin, keratinocytes were sorted based on
CD45+ and LCs were sorted based on MHC+. Real time PCR of RNA isolated from each
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cell type revealed that keratinocytes and LCs have a different expression profile in
response to DMBA. LCs did not express Cyp1a1 either before or after DMBA, while
there was a two-fold increase in AhR, Cyp1b1, and EPXH1 after DMBA. Overall enzyme
expression levels were greater in keratinocytes than LCs, however keratinocytes heavily
favored Cyp1a1 expression over Cyp1b1 (Figure 6, A and B). Thus, the Cyp1b1 to
Cyp1a1 ratio was 0.108 in keratinocytes, whereas it approached infinity LCs.
Given that these data indicate the major contribution of murine LCs to cutaneous
chemical carcinogenesis is mediated by non-immunological properties, it was appropriate
to determine whether human LCs might display equivalent properties with the potential
to facilitate disease. We therefore examined the response to DMBA of primary human
LCs from several donors, and their consequent effects on primary keratinocytes. The data
are consistent with the murine data sets and previous reports in the literature [56].
Following DMBA treatment, human LCs express substantially more Cyp1b1 than
Cyp1a1 (of which most donors’ cells express negligible levels), whereas human
keratinocytes express an excess of Cyp1a1 (Figure 6C). For most donors, Cyp1b1
expression by DMBA-treated LC was ~20-fold higher than that in keratinocytes, whereas
Cyp1a1 expression was substantially higher in keratinocytes.
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Figure 6:

C

G. LC-deficient mice develop UVB-induced tumors at the same rate as wild type
mice
The data presented thus far implied that the LC contribution to carcinogenesis is
unique to the chemical carcinogenesis model. We questioned if the profound resistance
seen in chemically treated LC-deficient mice would be observed in UVB-carcinogenesis
protocols. In order to investigate the impact of LC-deficiency on UVB-induced tumors,
huLang.DTA mice and NLC mice underwent daily UVB treatment five days per week for
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thirty weeks. Four out of ten NLC mice harbored tumors by week 24 of treatment,
whereas all LC-deficient mice remained tumor-free (Figure 7A). NLC mice harbored
significantly more tumors and a significantly larger tumor area early during tumor
development. On week 24, average tumor number per mouse was 0.5±0.2 for NLC and 0
for DTA mice (p-value = 0.019). Average tumor area was 5.6mm2±2.8 for NLC and 0 for
DTA mice (p-value = 0.031). With continued UVB treatment, however, DTA mice began
developing tumors. At week 29 (Figure 7B), there was no longer a statistically
significant difference between the two cohorts. Average tumor number per mouse was
2.5±0.69 for NLC and 1.6±0.27 for DTA mice (p-value = non-significant). Thus, LCdeficiency did not protect against UVB-induced tumors, although it did delay onset of
tumors by a short period of time.

Figure 7A: Tumor number and tumor area per mouse at 24 weeks of UVB treatment.

Figure 7B: Tumor number and tumor area per mouse at 29 weeks of UVB treatment.
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V. Discussion
The immunological influences on cancer biology elucidated to date traverse a
wide range of effects. Clinical evidence definitively demonstrates that the immune
system is intimately related to cancer in both enhancing and inhibiting capacities. As the
major immune constituents present in mouse epidermis, γδ DETCs and LCs represent the
interface of the immune system and cutaneous epithelial tumors. Furthermore, the skin
epithelial surface faces with an ever-growing level of mutagenic PAHs found in the
environment. While γδ DETCs provide an anti-tumor effect on chemical carcinogenesis
in which their absence leads to higher rates of tumors [14], LCs contribute an effect so
critical to tumorigenesis that their absence results in nearly complete elimination of
DMBA/TPA-induced cutaneous papilloma and squamous cell carcinoma [27].
With dendritic processes extending in all directions, LCs are strategically
positioned to interact with carcinogenic compounds in the environment and the
keratinocyte stem cells of the epidermis [1]. Until the development of LC-deficient
mouse models, our understanding of LC biology has primarily centered on its role in
antigen presentation and regulating an adaptive immune response [22]. Here, we shift the
LC-paradigm further and describe a novel pathophysiologic role for LC in the
development of cancer that is independent of αβ and γδ T cell-mediated immunity
(Figure 1). LC-deficient epidermis harbored fewer Hras1 mutations than wild type skin
(Figure 3); in vitro LC generated the proximate carcinogen DMBADE (Figure 4); and
direct initiation with DMBA-trans-3,4-diol restored tumorigenesis on DTA mice (Figure
5). LC-deficiency did not eliminate UVB-carcinogenesis, although tumors developed
later than LC-intact mice (Figure 7). Thus, our data collectively demonstrate that LCs
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facilitate carcinogenesis in neighboring keratinocytes through inherent scavenging
properties and enzymatic processing that generates the critical mutagenic metabolites.

A. RATIO HYPOTHESIS
Our findings further suggest that keratinocytes, by themselves, are inadequate in
unleashing DMBA’s mutagenic potential, and investigations into the cell-specific
expression of XRE enzymes reveal a possible explanation. In both mice and humans, we
observed a preferential expression of Cyp1B1 > Cyp1A1 in LC and Cyp1A1 > Cyp1B1 in
keratinocyte (Figure 6). Invoking the conclusions of Kleiner and Buters that Cyp1B1 is
required for generation of mutagenic intermediates [47] and that Cyp1A1 has a faster
pharmacokinetics profile [46], it follows that the low Cyp1B1 to Cyp1A1 ratio in
keratinocytes would skew metabolism towards generation of non-mutagenic metabolites
mediated predominantly by Cyp1A1. The high ratio of Cyp1B1 to Cyp1A1 in LCs enables
these cells to preferentially generate the proximate carcinogen DMBA-trans-3,4-diol.
Others have revealed the potential for non-epithelial stromal cells to activate PAHs [63,
64]. The observation of decreased Hras1 mutations in LC-deficient mice, in which
keratinocytes are normal and abundant, offers in vivo evidence to reject that keratinocyte
XRE enzymes are the metabolic machinery catalyzing DMBA activation. The lack of
tumors in LC-deficient mice further recapitulates this notion.
The relevance of Cyp1B1 to cancer biology has been investigated from many
aspects. For instance, it is expressed at higher levels in tumor samples compared to
normal counterparts [65]. Individuals who smoke cigarettes, which contains the PAH BP,
preferentially express Cyp1B1 in their oral mucosa [66]. However, while Cyp1B1-
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mediated metabolism contributes to PAH-carcinogenesis [44, 46], data derived from
colonic adenocarcinoma models suggest that Cyp1B1 is protective against endogenous
carcinogenic substrates [67]. Thus, these data offer a teleological explanation for why LC
may have evolved a “cancer-promoting” Cyp1B1:Cyp1A1 ratio. The increased
interactions between PAH and the epidermis in industrialized societies perhaps facilitate
the hijacking of a protective effect that LC Cyp1B1 evolved to perform. Future
investigations should pursue the development of an LC-specific Cyp1B1 knockout mice.
The use of this animal model would not only confirm the findings presented herein if
resistance to DMBA carcinogenesis is observed, but it would also facilitate investigations
into the positive roles of LC Cyp1B1.

B. COOPERATIVE CARCINOGENESIS
LCs are located adjacent to both inter- and intra- follicular basal keratinocytes
[68], and hair follicle bulge cells have been strongly implicated as targets of cutaneously
applied chemical mutagens [69]. Given LC and keratinocyte stem cell proximity, our data
imply a cooperative carcinogenesis scenario in which keratinocyte mutagenesis requires
neighboring LC-mediated DMBA activation (Diagram 2). In this proposed model, LC
must first internalize DMBA (1), perhaps via simple diffusion or through a more
sophisticated process such as endocytosis. Next, LC-specific Cyp1B1 and EPXH1
generate DMBA-trans-3,4-diol (1), which then traverse out of LC and into adjacent
keratinocytes (2) for further metabolism to DMBADE. Within keratinocytes, the ultimate
carcinogen displays a well-described, strong affinity for the Hras gene at codon 61 (3)
[35]. Intercellular metabolite transfer has been proposed in other models examining
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DMBA’s effects, which corroborate that non-epithelial “stromal” cells are critical for
DMBA-activation [54, 55].

Diagram 2: Cooperative Carcinogenesis Scenario

C. IMPLICATIONS FOR OTHER CUTANEOUS AND NON-CUTANEOUS TUMORS
LCs neighbor other epidermal cellular constituents including melanocytes. Their
proximity, coupled with the increasing body of evidence that activation of the ras family
of oncogenes is necessary for human melanoma development [70], implicates LCmediated cooperative carcinogenesis and PAH in melanoma biology. Although patients
with human familial melanoma syndromes – alterations in Cdkn2a and/or Cdk4 – exhibit
a higher incidence of clinical melanomas, mice genetically engineered to mimic these
syndromes result in a very low incidence of spontaneous melanoma [71]. In these
animals, the high melanoma incidence is restored by inducible expression of Hras [72].
Removal of the inducible signal, and thus Hras expression, resulted in regression of pre-
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existing melanomas [72]. Indeed, in mice with low melanoma incidence despite
expressing alterations in Cdk4, DMBA treatment also restored heightened melanoma
development [73, 74]. The melanocytes of human Spitz nevi have been shown to possess
mutations and copy number amplifications of the Hras gene [75]. Thus, these findings
warrant further investigation into the contribution of LC-mediated metabolism of PAH to
pigment cell ras activation.
Furthermore, our findings hold implications for carcinoma of non-cutaneous
epithelial tissues, such as the GI and respiratory tracts. Arguably, these epithelial surfaces
are exposed to some of the highest levels of PAHs secondary to their presence in certain
foods and cigarette smoke. The presence of intraepithelial immune cells in these noncutaneous epithelial surfaces raises the possibility that tissue specific immune cells might
have similar non-immunologic contributions to PAH-mutagenesis. Our findings justify
future investigations to evaluate XRE expression profiles of other tissue-specific
dendritic cells.

Our findings offer a novel target for the reduction in PAH-induced ras mutations
in non-melanoma skin cancers, and possibly for melanoma and epithelial transformations
throughout the body. With therapies targeting LC-specific Cyp1B1 metabolism, perhaps
the mutagenic effects of PAH found in the environmental, cigarette smoke, and certain
foods may be mitigated. Nevertheless, these findings demonstrate that tissue-associated
DC can enhance chemical carcinogenesis via PAH metabolism, highlighting the complex
relation between immune cells and carcinogenesis.
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VI. Figure Legends
Diagram 1. DMBA metabolism pathway. The metabolism of DMBA to the principle
proximate carcinogen DMBA-trans-3,4-diol and the ultimate mutagen DMBADE is
depicted as adapted from Miyata, et al. [49]

Figure 1. Resistance to two-stage chemical carcinogenesis is αβ and γδT cell–
independent. Chemical carcinogenesis was induced in (A) Tcrβ−/− Tcrδ−/− Lang-DTA
mice using 50 mg DMBA to initiate and 6.25 mg TPA/week to promote, as well as in (B)
Tcrδ−/− Lang-DTA mice using 100 mg DMBA to initiate and 25 mg TPA/week to
promote. The mean numbers of tumors per mouse (left) and individual tumor area (right)
14 weeks post-initiation are shown. ***P < 0.0001 (Student’s t test); n = 8 to 12 mice per
group. NS, not significant. (C) Representative images from (B).

Figure 2. LC-deficiency does not prevent tumorigenesis in K5Hras mice. K5HrasTgLang-DTA and K5HrasTg littermates were monitored for spontaneous tumor
development. LC-deficient and LC-intact mice had equivalent tumor incidence and
individual tumor area.

Figure 3. DMBA induces fewer Hras mutations in LC-deficient mice than in wild
type mice. (A) Hras1 240bp PCR product containing codon-61 was cloned from CarC
(mutant) and mKC (WT) cell gDNA and inserted into pcDNA6.2TM/GW/D-TOPO®
expression vector and sequenced for verification. (B) Real time PCR using mutantspecific primers was done with a known absolute number of plasmids per reaction in
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order to determine the lower limit of mutant copy detection. As few as 8 mutant plasmids
were detected in this system, while normal plasmids were not detectable with mutant
primers. (C) DMBA was applied to the dorsal skin of both NLC and DTA mice, followed
by application of 2, 4, or 6 weeks of TPA (twice/week). DNA was harvested for mutation
quantification. DNA from LC-intact skin harbored more Hras-61 mutants than DNA
from LC-deficient skin *P < 0.05 (Student’s t test), in a TPA-dose dependent manner.
LC-deficiency protected against acquiring Hras-61 mutation even in the absence of αβ
and γδ T cells *P < 0.05 (Student’s t test).

Figure 4. XS106 cells cultured with DMBA generate DMBA-trans-3,4-diol. XS106
cells were cultured with 64 mM DMBA for 24 hours, the supernatant was then collected,
and cells were pelleted to prepare a lysate. (A and C) HPLC analysis of the lysate. (B, D,
and E) HPLC analysis of the supernatant. (F) LC/MS/MS analysis of XS106 cells in the
presence or absence of DMBA.

Figure 5. Initiation with DMBA-trans-3,4-diol restores tumorigenesis in the DTA
mouse. (A) Tumor induction was measured after treatment with DMBA (12.5 mg) or
DMBA-trans-3,4-diol (100 mg). 25 mg/week TPA promotion was used in both groups,
and initiator doses were chosen on the basis of predicted diol instability, reduced
cutaneous penetrance, and preliminary studies. Each dot represents an individual mouse.
***P < 0.0001 (Student’s t test). (B and C) Representative images from (A).

Figure 6. KC XRE expression favors Cyp1A1, while LC expression favors Cyp1B1.
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Primary murine LCs (A) and keratinocytes (B) were cultured with and without DMBA
for 24 hours, after which Cyp1B1 to Cyp1A1 expression was quantified relative to β-actin
by qPCR. (C) Human keratinocytes or LCs were cultured in the presence (right) or
absence (left) of 64 mM DMBA for 24 hours, then Cyp1a1 (1A1) and Cyp1b1 (1B1)
expression was quantified relative to β-actin by qPCR.

Figure 7. LC-deficient mice develop UVB-induced tumors at the same level as LCintact mice. Tumor induction was measured as tumor number and tumor area at (A) 24
weeks and again at (B) 29 weeks post-initiation of 5-time weekly UVB treatment.

Diagram 2. Cooperative chemical carcinogenesis scenario. Illustration of proposed
mechanism by which LCs contribute to chemical carcinogenesis. (1) LCs internalize
DMBA, where LC-specific CYP1B1 and mEH convert DMBA to DMBA-trans-3,4-diol.
(2) This metabolite moves out of LCs and into keratinocytes where it undergoes further
metabolism to DMBADE. (3) The ultimate mutagen exerts effects on keratinocyte Hras
gene.

Image 1. LC internalize DMBA. Confocal image depicting MHCII+ (green) cells
internalizing DMBA (blue). Taken by Julia Lewis.
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